Table 2.
Comparison of the underlying diseases between the 2 groups
| Baseline data | Cisplatin group (n=109) |
Nedaplatin group (n=110) |
P-value |
|---|---|---|---|
| Karnofsky score | 77.52±8.84 | 77.73±10.01 | 0.646 |
| Underlying malignancy, n (%) | 0.895 | ||
| Lung cancer | 57 (52.29) | 58 (52.73) | |
| Colon cancer | 9 (8.26) | 7 (6.36) | |
| Breast cancer | 24 (22.02) | 28 (25.45) | |
| Gastric cancer | 8 (7.34) | 9 (8.18) | |
| Rectal cancer | 11 (10.09) | 8 (7.27) | |
| Tumor pathology, n (%) | 0.708 | ||
| Infiltrative cancer | 17 (15.60) | 18 (16.36) | |
| Squamous cell cancer | 33 (30.28) | 25 (22.73) | |
| Adenocarcinoma | 37 (33.94) | 39 (35.45) | |
| Small-cell lung cancer | 11 (10.09) | 16 (14.55) | |
| Other | 11 (10.09) | 12 (10.91) | |
| Mediastinal metastasis, n (%) | 40 (36.70) | 50 (45.45) | 0.188 |
| Pleural effusion volume, n (%) | 0.656 | ||
| Large | 47 (43.12) | 52 (47.27) | |
| Medium | 24 (22.02) | 19 (17.27) | |
| Small | 38 (34.86) | 39 (35.45) | |
| Cachexia, n (%) | 6 (5.50) | 7 (6.36) | 0.788 |
| Targeted therapy, n (%) | 6 (5.50) | 7 (6.36) | 0.788 |
| Concomitant chemotherapy with the intrapleural treatment, n (%) | 8 (7.34) | 10 (9.09) | 0.637 |
Note: Data presented as mean ± SD.